Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Chad Mirkin
Northwestern University at Chicago, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Exicure
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
This research tests therapeutic approaches using engineered nanoparticles and spherical nucleic acids that are license to Exicure (previously AuraSense Therapeutics, LLC) an entity in which Professor Mirkin is a founder and discloses both receipt of remuneration and equity interest. Given the close relationship of the work and goals of Exicure and this project, continued development of these spherical nucleic acids funded through this grant may result in a perceived conflict of interest that should be managed.
Note: Exicure has recently gone public; the relationship with the company has been managed and was previously reported per FCOI report 9798. That report will be ended given the change in status of the company from private to public, and future reports will follow this one.
Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer
Northwestern University Center of Cancer Nanotechnology Excellence (NU-CCNE) for Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer Northwestern University PIs: Chad A. Mirkin and Leonidas Platanias Much still remains to be learned about the genetic basis of cancer and how it can be analyzed and treated. Current treatment methodologies fall short of providing efficacious, targeted, precision therapies geared towards the individual patient. Due to their novel chemical, biological, and physical properties, nucleic-acid based nanoconstructs can be used to gain access to privileged intracellular environments, discover new aspects of cancer biology, and exploit nanostructure-biomolecular interactions to create effective treatment options. The Center of Cancer Nanotechnology Excellence for Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer, headquartered at Northwestern University (NU), proposes to explore these vast possibilities by applying a novel class of nanostructure genetic constructs - the spherical nucleic acid and variants of it - for the study and treatment of brain and prostate cancer.
Filed on July 09, 2018.
Tell us what you know about Chad Mirkin's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Chad Mirkin filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | $100,000 - $149,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | $100,000 - $149,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | AuraSense Therapeutics, LLC | $5,000 - $9,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | AuraSense, LLC | Value cannot be readily determined |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | AuraSense Therapeutics, LLC | Value cannot be readily determined |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.